CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOU

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 中心，但不一定是研究者所在的机构。 有人提出，CD 40配体（CD 40 L）在体内增强白血病抗原呈递的能力，作为共刺激分子发挥作用，并诱导IL-2释放，这些都有助于募集特异性T细胞和NK细胞抗白血病效应机制，然后IL-2能够进一步扩增这些机制。1）为了确定来自慢性淋巴细胞白血病（B-CLL）患者的自体恶性B细胞的三至六次皮下（SC）注射的安全性，其已被离体修饰以分泌人白细胞介素-2（hIL-2）并表达人CD 40配体（hCD 40 L）。2)确定通过SC注射B-CLL细胞是否诱导MHC限制性或非限制性抗肿瘤免疫应答，所述B-CLL细胞已经离体修饰以分泌hIL-2并表达hCD 40 L。3）获得关于该治疗方案的抗肿瘤作用的初步数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is proposed that the ability of CD40 Ligand (CD40L) to enhance leukemia antigen presentation in vivo, to act as a co-stimulator molecule and to induce IL-2 release all serve to recruit both specific T cell and NK cell anti-leukemia effector mechanisms, which IL-2 is then able to further amplify.SPECIFIC AIMS¿1) To determine the safety of three to six subcutaneous (SC) injections of autologous malignant B cells from chronic lymphocytic leukemia (B-CLL) patients, which have been modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L). 2) To determine whether MHC- restricted or unrestricted anti-tumor immune responses are induced by SC injections of B-CLL cells which have been modified ex vivo to secrete hIL-2 and to express hCD40L.3) To obtain preliminary data on the anti-tumor effects of this treatment regimen.